Mark S Sulkowski

Author PubWeight™ 130.41‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011 19.01
2 Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009 14.31
3 Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013 8.49
4 Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011 6.31
5 Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010 6.14
6 Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014 3.40
7 Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013 3.30
8 Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol 2007 2.58
9 Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014 2.54
10 Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. Hepatology 2010 2.53
11 Needlestick injuries among surgeons in training. N Engl J Med 2007 2.37
12 Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004 2.28
13 Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology 2014 2.17
14 Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology 2014 2.04
15 Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012 1.95
16 Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med 2015 1.94
17 Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA 2012 1.88
18 Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003 1.83
19 Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS 2006 1.82
20 Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology 2013 1.63
21 Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol 2011 1.59
22 Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology 2010 1.53
23 Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1. Gastroenterology 2010 1.35
24 Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events. AIDS 2008 1.32
25 Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology 2012 1.31
26 Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004 1.30
27 Racial differences in hepatitis C treatment eligibility. Hepatology 2011 1.28
28 A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV/HCV-co-infected injection drug users. AIDS 2005 1.25
29 Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin. Hepatology 2012 1.19
30 The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology 2005 1.17
31 Treatment of chronic hepatitis C: a systematic review. Hepatology 2002 1.14
32 The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons. J Acquir Immune Defic Syndr 2003 1.13
33 Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs. Hepatology 2014 1.08
34 Daclatasvir plus sofosbuvir for HCV infection. N Engl J Med 2014 1.04
35 Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immune reconstitution. AIDS 2009 1.00
36 Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Gut 2011 1.00
37 All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection. Hepatology 2014 0.98
38 Antiretroviral-associated liver injury. Clin Liver Dis 2003 0.97
39 Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop. Am J Gastroenterol 2010 0.95
40 A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. Antivir Ther 2006 0.93
41 Treatment of chronic hepatitis B in HIV-infected persons: thinking outside the black box. Clin Infect Dis 2005 0.93
42 Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons. Clin Infect Dis 2012 0.93
43 Protective interleukin-28B genotype affects hepatitis C virus clearance, but does not contribute to HIV-1 control in a cohort of African-American elite controllers/suppressors. AIDS 2011 0.92
44 Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration. Am J Gastroenterol 2008 0.91
45 Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3. Clin Gastroenterol Hepatol 2011 0.91
46 Controlled HIV viral replication, not liver disease severity associated with low bone mineral density in HIV/HCV co-infection. J Hepatol 2011 0.90
47 Stability of liver fibrosis among HCV-infected injection drug users. Antivir Ther 2012 0.89
48 Hepatitis C virus in the setting of HIV or hepatitis B virus coinfection. Semin Liver Dis 2004 0.88
49 Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial. J Acquir Immune Defic Syndr 2005 0.85
50 Hepatic profile analyses of tipranavir in Phase II and III clinical trials. BMC Infect Dis 2009 0.85
51 Analysis of site performance in academic-based and community-based centers in the IDEAL Study. J Clin Gastroenterol 2013 0.85
52 Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials. Liver Int 2013 0.84
53 Vitamin D deficiency and its relation to bone mineral density and liver fibrosis in HIV-HCV coinfection. Antivir Ther 2012 0.83
54 Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-α-2a and ribavirin in HIV/HCV co-infected patients. J Hepatol 2010 0.82
55 Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection. J Clin Virol 2006 0.79
56 Hepatic steatosis associated with increased central body fat by dual-energy X-ray absorptiometry and uncontrolled HIV in HIV/hepatitis C co-infected persons. AIDS 2010 0.78
57 Modulation of interferon-specific gene expression by albumin-interferon-alpha in interferon-alpha-experienced patients with chronic hepatitis C. Antivir Ther 2006 0.77
58 Defining the standard of care: randomized controlled trials for the treatment of hepatitis C in the HIV-infected person. Hepatology 2004 0.77
59 Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C. Clin Gastroenterol Hepatol 2008 0.77
60 Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype. Hepatology 2010 0.76
61 Hepatitis C virus: a critical appraisal of new approaches to therapy. Hepat Res Treat 2012 0.76
62 Regression of splenic lymphoma after treatment of hepatitis C virus infection. N Engl J Med 2002 0.75
63 Antiretroviral therapy, interferon sensitivity, and virologic setpoint in human immunodeficiency virus/hepatitis C virus coinfected patients. Hepatology 2014 0.75
64 Predictors of consent to pharmacogenomics testing in the IDEAL study. Pharmacogenet Genomics 2013 0.75
65 Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL study. Clin Infect Dis 2014 0.75
66 Global transcriptional effects of PEG-IFN-alpha and ribavirin on peripheral blood cells obtained from patients with chronic hepatitis C. Hepatol Res 2006 0.75
67 Should a prisoner be placed on the organ transplant waiting list? Virtual Mentor 2008 0.75
68 Detection of liver disease in injection drug users. J Addict Dis 2008 0.75